Related Experiment Video
Updated: Aug 14, 2026
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells
Aikaterini Anagnostopoulou1, Adina Vultur, Rozanne Arulanandam
1Department of Microbiology, Queen's University, Kingston, Ont., Canada K7L3N6.
Abstract:
The signal transducer and activator of transcription-3 (Stat3) is persistently activated in many cancers such as cancer of the breast and is required for transformation by a number of oncogenes. Signaling through Stat3 is determined by a key phosphorylation at tyr-705. We previously demonstrated that cell-to-cell adhesion brought about through cell aggregation or confluence of cultured cells causes a dramatic increase in Stat3 tyr705 phosphorylation and consequently Stat3 activity in both normal and tumor cells. To examine the role of Stat3 at specific time-points relative to confluence, we used two different approaches of Stat3 inhibition: (1). Introduction of high levels of peptide analogues, which block the Stat3-SH2 domain, to inhibit Stat3 binding to and phosphorylation by growth factor receptors. (2). Treatment with two platinum compounds which bind the Stat3 protein and inhibit its activity without affecting its phosphorylation directly. The results demonstrate that Stat3 downregulation in vSrc transformed NIH3T3 cells or in breast cancer lines harboring activated Src induces apoptosis, which is evident at all densities but is more pronounced at post-confluence. In normal cells on the other hand, Stat3 inhibition at post-confluence caused apoptosis while in sparsely growing cells it induced merely a growth retardation.
Insights
Signal transducer and activator of transcription-3 (Stat3) inhibition induces apoptosis in cancer cells, particularly at high densities. In normal cells, Stat3 inhibition causes growth retardation or apoptosis depending on cell density.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Signal transducer and activator of transcription-3 (Stat3) is crucial for cancer development and transformation, with persistent activation observed in various cancers, including breast cancer.
- Stat3 signaling is regulated by phosphorylation at tyr-705, which is significantly increased by cell-to-cell adhesion and confluence.
- Cell density and cell-to-cell contact dynamically influence Stat3 activity in both normal and tumor cells.
Purpose of the Study:
- To investigate the role of Stat3 at specific time points relative to cell confluence.
- To determine the differential effects of Stat3 inhibition on cancer cells versus normal cells at varying densities.
Main Methods:
- Utilized two distinct Stat3 inhibition strategies: peptide analogues targeting the Stat3-SH2 domain and platinum compounds inhibiting Stat3 activity directly.
- Examined Stat3 downregulation in vSrc-transformed NIH3T3 cells and breast cancer lines with activated Src.
- Assessed the impact of Stat3 inhibition on apoptosis and cell growth in both normal and tumor cell lines at different cell densities (sparse vs. post-confluence).
Main Results:
- Stat3 downregulation induced apoptosis in cancer cells (vSrc-transformed NIH3T3 and breast cancer lines), with a more pronounced effect at post-confluence densities.
- In normal cells, Stat3 inhibition at post-confluence led to apoptosis.
- In sparsely growing normal cells, Stat3 inhibition resulted in growth retardation rather than apoptosis.
Conclusions:
- Stat3 plays a critical role in cancer cell survival and proliferation, making it a potential therapeutic target.
- The effect of Stat3 inhibition is context-dependent, varying between cancer and normal cells, and influenced by cell density.
- Targeting Stat3 offers a promising strategy for cancer therapy, with potential for differential effects on tumor versus normal tissues.
